Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection

Risk adjusted Net Present Value (rNPV) for TVGN 116 is estimated to exceed ~$325 million in the US alone. WARREN, N.J., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today shared asset value and potential forecast for the Company’s pipeline product, TVGN 116, for liver cancer prevention with high-risk chronic Hepatitis B infections. The TVGN 116 cumulative 5-year top-line revenue forecast is estimated to be ~$6.5 billion. The forecast reflects the Comp ...